|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 48/00 | |
| A61K 31/7105 | |||
| C12N 15/113 | |||
| A61P 35/00 | |||
| A61K 38/17 |
| (11) | Number of the document | 2470217 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10812443.9 |
| Date of filing the European patent application | 2010-02-19 | |
| (97) | Date of publication of the European application | 2012-07-04 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/024740 |
| Date | 2010-02-19 |
| (87) | Number | WO 2011/025556 |
| Date | 2011-03-03 |
| (30) | Number | Date | Country code |
| 708294 | 2010-02-18 | US | |
| 546292 | 2009-08-24 | US |
| (72) |
DONALD, Carlton, D., US
|
| (73) |
Phigenix, Inc.,
191 Peachtree Street, Suite 3300, Atlanta, GA 30303,
US
|
| (54) | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER |
| TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER |